Director, Mbdc, Dghs Pharmaceutical Import Profile — Bangladesh (DGFT 2022–2026)

Name: Director, Mbdc, Dghs Pharmaceutical Import Records from India — 2 Products, $1.9M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Director, Mbdc, Dghs — Pharmaceutical Importer Profile (2026) | 2 Products, $1.9M Trade | TransData Nexus

Director, Mbdc, Dghs

Pharmaceutical Importer · Bangladesh · Tuberculosis Medications Focus · $1.9M Total Trade · DGFT Verified

Director, Mbdc, Dghs is a pharmaceutical importer based in Bangladesh with a total trade value of $1.9M across 2 products in 2 therapeutic categories. Based on 39 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Director, Mbdc, Dghs sources from 2 verified Indian suppliers, with Lupin Limited accounting for 87.5% of imports.

Director, Mbdc, Dghs — Import Portfolio & Supplier Network

Director, Mbdc, Dghs import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Director, Mbdc, Dghs?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Lupin Limited	$350.0K	7	87.5%
Macleods Pharmaceuticals Limited	$50.0K	1	12.5%

Director, Mbdc, Dghs sources from 2 verified Indian suppliers across 4 distinct formulations.

What Formulations Does Director, Mbdc, Dghs Import?

Formulation	Value	Ships
Rifa 75 & iso 50 TAB 3x28t gdf (pedia) rifampin and isoniazid dispersible tablets. (46556 Box	$150.0K	3
Rifa 75 & iso 50 TAB 3x28t gdf (pedia) rifampin and isoniazid dispersible tablets. (46672 Box	$150.0K	3
Rifapentine 300 + inh 300 TAB 3x12t rifapentine and isoniazid tablets. (25214 Box)	$50.0K	1
Ethambutol hydrochloride dispersible tablets 100MG(5534 packs,size:10x10)(batchno.nee2503a mfd.01/25 exd.12/27	$50.0K	1

Director, Mbdc, Dghs imports 4 distinct pharmaceutical formulations. Showing top 4 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Isoniazid	Tuberculosis Medications	$1.1M	22	0.0%	5
2	Rifampicin	Advanced Antibiotics	$850.0K	17	0.1%	4

Director, Mbdc, Dghs imports 2 pharmaceutical products across 2 categories into Bangladesh totaling $1.9M.

Director, Mbdc, Dghs — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Director, MBDC, DGHS is a governmental entity operating under the Directorate General of Health Services (DGHS) in Bangladesh. The DGHS is the principal authority responsible for the planning, development, and management of the country's health services. The MBDC (Medical Supplies and Drug Control) division within DGHS oversees the procurement and distribution of medical supplies and pharmaceuticals to ensure the availability of essential medicines across Bangladesh. Headquartered at the Leprosy Hospital Compound, TB Gate, Mohakhali, Dhaka-1212, Bangladesh, the MBDC plays a pivotal role in the national healthcare supply chain. (csc.dghs.gov.bd)

As a government procurement agency, Director, MBDC, DGHS is tasked with sourcing and importing pharmaceutical products to meet the country's medical needs. This includes managing the importation of finished pharmaceutical formulations, such as tablets, capsules, syrups, and injections, from various international suppliers. The agency's operations are integral to maintaining a steady supply of essential medicines, thereby supporting the overall healthcare infrastructure in Bangladesh.

2Distribution Network

While specific details about the distribution network of Director, MBDC, DGHS are not publicly disclosed, it is understood that the agency's operations are centralized at its headquarters in Dhaka. The DGHS, under which MBDC operates, is responsible for the nationwide distribution of medical supplies and pharmaceuticals. This centralized approach ensures that medical products are efficiently distributed to various healthcare facilities across Bangladesh, including hospitals, clinics, and health centers. The logistics capabilities of the DGHS are designed to support the timely delivery of medical supplies to meet the country's healthcare demands.

3Industry Role

Director, MBDC, DGHS functions as a government procurement agency within Bangladesh's pharmaceutical supply chain. Its primary role is to source and import finished pharmaceutical formulations to ensure the availability of essential medicines nationwide. By managing the procurement process, MBDC plays a critical role in maintaining the stability and reliability of the country's pharmaceutical supply, directly impacting the quality and accessibility of healthcare services.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Director, Mbdc, Dghs

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

The sourcing data indicates that Director, MBDC, DGHS imports a limited range of pharmaceutical products, specifically focusing on two therapeutic categories: Tuberculosis Medications and Advanced Antibiotics. This concentration suggests a strategic approach to procurement, aligning with the national health priorities of combating tuberculosis and addressing antibiotic resistance. The agency's reliance on a small number of suppliers, notably LUPIN LIMITED and MACLEODS PHARMACEUTICALS LIMITED, indicates a preference for established partnerships to ensure consistent quality and supply. However, this limited supplier base may pose risks related to supply chain disruptions or changes in supplier dynamics.

The shipment data reveals that LUPIN LIMITED has been the primary supplier, accounting for 87.5% of the shipments, while MACLEODS PHARMACEUTICALS LIMITED contributed 12.5%. This distribution reflects a strong reliance on LUPIN LIMITED, which could be advantageous in terms of negotiating favorable terms and ensuring product consistency. However, such dependency also underscores the importance of maintaining a robust relationship with these suppliers and having contingency plans in place to mitigate potential risks.

2Supply Chain Resilience

The supply chain resilience of Director, MBDC, DGHS appears to be moderately robust, given its reliance on two primary suppliers for a limited range of products. The agency's focus on finished pharmaceutical formulations from India, particularly from suppliers like LUPIN LIMITED and MACLEODS PHARMACEUTICALS LIMITED, suggests a streamlined procurement process. However, the limited number of suppliers may expose the supply chain to risks such as supply disruptions, geopolitical issues, or changes in supplier policies. To enhance resilience, it would be prudent for MBDC to diversify its supplier base and establish contingency plans to ensure a continuous supply of essential medicines.

Importing Pharmaceuticals into Bangladesh — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Bangladesh

1Regulatory Authority & Framework

In Bangladesh, the Directorate General of Drug Administration (DGDA) is the primary regulatory authority overseeing the pharmaceutical sector. The DGDA is responsible for ensuring the safety, efficacy, and quality of drugs and pharmaceutical products within the country. Key legislation governing pharmaceutical imports includes the Drugs Act, 1940, and the Drugs (Control) Ordinance, 1982, which provide the legal framework for drug regulation and control. The DGDA's role encompasses the registration of pharmaceutical products, monitoring of manufacturing practices, and enforcement of standards to safeguard public health.

For Indian pharmaceutical exporters, understanding the regulatory framework is crucial. The DGDA requires that all imported pharmaceutical products be registered and approved before they can be marketed in Bangladesh. This process involves submitting detailed documentation, including product dossiers, manufacturing licenses, and certificates of analysis. Compliance with Good Manufacturing Practice (GMP) standards, as recognized by the World Health Organization (WHO) or the Pharmaceutical Inspection Co-operation Scheme (PIC/S), is mandatory for all imported pharmaceutical products. Adhering to these regulations ensures that products meet the safety and quality standards required for the Bangladeshi market.

2Import Licensing & GMP

Director, Mbdc, Dghs — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Director, MBDC, DGHS's focus on importing tuberculosis medications and advanced antibiotics aligns with Bangladesh's national health priorities. Tuberculosis remains a significant public health concern in the country, necessitating a steady supply of effective medications. Advanced antibiotics are essential for treating complex infections and combating antibiotic resistance. The market demand for these products is driven by the prevalence of infectious diseases and the need for effective treatment options. By concentrating on these therapeutic areas, MBDC ensures that critical medical needs are met, thereby supporting the overall healthcare infrastructure in Bangladesh.

2Sourcing Profile

Director, MBDC, DGHS's sourcing strategy involves importing generic drugs, particularly those used in the treatment of tuberculosis and complex infections. The agency's preference for finished pharmaceutical formulations indicates a focus on ready-to-use products that can be immediately distributed within the healthcare system. India's pharmaceutical industry, with its robust manufacturing capabilities and adherence to international quality standards, fits well into MBDC's procurement strategy. For Indian exporters, understanding MBDC's focus on these therapeutic areas and product types is essential for aligning their offerings with the agency's requirements.

Market Positioning

Frequently Asked Questions — Director, Mbdc, Dghs

What products does Director, Mbdc, Dghs import from India?

Director, Mbdc, Dghs imports 2 pharmaceutical products across 2 categories. Top imports: Isoniazid ($1.1M), Rifampicin ($850.0K).

Who supplies pharmaceuticals to Director, Mbdc, Dghs from India?

Director, Mbdc, Dghs sources from 2 verified Indian suppliers. The primary supplier is Lupin Limited (87.5% of imports, $350.0K).

What is Director, Mbdc, Dghs's total pharmaceutical import value?

Director, Mbdc, Dghs's total pharmaceutical import value from India is $1.9M, based on 39 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Director, Mbdc, Dghs focus on?

Director, Mbdc, Dghs imports across 2 categories. The largest: Tuberculosis Medications (56.4%), Advanced Antibiotics (43.6%).

Get Full Director, Mbdc, Dghs Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.